Ocular Therapeutix (OCUL) Reports First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for Treatment of Dry Eye Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. HUVR:IN
2. TAP
3. DELL
4. ROIV
5. ANET
6. NKE
7. PANW
8. CL
9. SNDK
10. SPG

Go back to Ocular Therapeutix (OCUL) Reports First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for Treatment of Dry Eye Disease
(NASDAQ: OCUL) Delayed: 10.64 --0 (-0%)
Previous Close $10.64    52 Week High $14.50 
Open $10.51    52 Week Low $4.04 
Day High $10.77    P/E N/A 
Day Low $10.51    EPS $0.00 
Volume 1,306,873